REPAGLINIDE Side Effects

6533648-9 | Blood Bilirubin Increased, Cholecystitis, Haematocrit Decreased, Haemoglobin Decreased, Hepatic Steatosis, Jaundice, Liver Disorder, Mean Cell Haemoglobin Concentration Decreased, Mean Cell Volume Increased
on Jan 08, 2010 Male patient from UNITED STATES , 65 years of age, weighting 244.3 lb, was diagnosed with diabetes mellitus and was treated with Repaglinide (View Usage). Patient experienced the following unwanted or unexpected effects: blood bilirubin increased, cholecystitis, haematocrit decreased, haemoglobin decreased, hepatic steatosis, jaundice (What is jaundice?), liver disorder, mean cell haemoglobin concentration decreased, mean cell volume increased. Repaglinide dosage: 0.5 Mg At Bedtime Po. Patient was hospitalized.

6377320-7 | Feeling Jittery, Hypoglycaemia, Nausea
Patient was taking Repaglinide (View Usage). Patient had the following side effects: feeling jittery, hypoglycaemia, nausea (What is nausea?) on Sep 23, 2009 from UNITED STATES Additional patient health information: Female patient , 64 years of age, was diagnosed with type 2 diabetes mellitus and. Repaglinide dosage: 4mg Po Tid Weeks. During the same period patient was treated with HEPARIN (View Heparin Review and Heparin Label ), RAMITIDINE (View Ramitidine Review and Ramitidine Label ), LEVOTHYROXINE SODIUM (View Levothyroxine Sodium Review and Levothyroxine Sodium Label ), SERTRALINE HYDROCHLORIDE (View Sertraline Hydrochloride Review and Sertraline Hydrochloride Label ), PREDNISONE (View Prednisone Review and Prednisone Label ), TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ).

6149616-5 | Atrioventricular Block, Hypoglycaemia, Hypotension, Ischaemic Hepatitis, Renal Failure
Adverse event was reported on Mar 30, 2009 by a Male patient taking Repaglinide (View Usage) (Dosage: Unk Mg, Qd) was diagnosed with type 2 diabetes mellitus, hypertension and. Location: FRANCE , 57 years of age, After Repaglinide was administered, patient had the following side effects: atrioventricular block, hypoglycaemia, hypotension, ischaemic hepatitis, renal failure. During the same period patient was treated with ISOPTIN (240 Mg, Qd) (View Isoptin Review and Isoptin Label ). Patient was hospitalized.

6141155-0 | Cerebral Haemorrhage, Hypoglycaemia, Vertigo
on Mar 23, 2009 Female patient from FRANCE , 82 years of age, was diagnosed with type 2 diabetes mellitus and was treated with Repaglinide (View Usage). Patient experienced the following unwanted or unexpected effects: cerebral haemorrhage, hypoglycaemia, vertigo. Repaglinide dosage: 6 Mg, Qd. During the same period patient was treated with INSULATARD FLEXPEN (20 Iu, Qd) (View Insulatard Flexpen Review and Insulatard Flexpen Label ), METFORMIN HCL (2 Df) (View Metformin Hcl Review and Metformin Hcl Label ), KARDEGIC /00002703/ (160 Mg, Qd) (View Kardegic /00002703/ Review and Kardegic /00002703/ Label ), ALTEIS (40 Mg, Unk) (View Alteis Review and Alteis Label ), ACEBUTOLOL (View Acebutolol Review and Acebutolol Label ), ARIMIDEX (View Arimidex Review and Arimidex Label ), PRAVASTATIN /00880402/ (View Pravastatin /00880402/ Review and Pravastatin /00880402/ Label ), LANSOPRAZOLE (View Lansoprazole Review and Lansoprazole Label ). Patient was hospitalized.


6109297-3 | Dehydration, Diarrhoea
on Feb 27, 2009 Female patient from GERMANY , 83 years of age, was diagnosed with type 2 diabetes mellitus and was treated with Repaglinide (View Usage). Patient had the following side effects: dehydration, diarrhoea. Repaglinide dosage: .5 Mg, Bid. During the same period patient was treated with CALCILAC KT (500 Mg, Qd) (View Calcilac Kt Review and Calcilac Kt Label ), METHIZOL (2.5 Mg, Qd) (View Methizol Review and Methizol Label ), ASPIRIN (100 Mg, Qd) (View Aspirin Review and Aspirin Label ), EXFORGE /01634301/ (5 Mg, Qd) (View Exforge /01634301/ Review and Exforge /01634301/ Label ), CARBAMAZEPINE (200 Mg, Qd) (View Carbamazepine Review and Carbamazepine Label ), TORSEMIDE (10 Mg, Unk) (View Torsemide Review and Torsemide Label ). Patient was hospitalized.

5959373-0 | Blood Glucose Decreased, Lethargy, Unresponsive To Stimuli
Patient was taking Repaglinide (View Usage). After Repaglinide was administered, patient had the following side effects: blood glucose decreased, lethargy, unresponsive to stimuli on Nov 19, 2008 from UNITED STATES Additional patient health information: Female patient , weighting 253.5 lb, was diagnosed with type 2 diabetes mellitus and. Repaglinide dosage: 4 Mg 3 X Day. During the same period patient was treated with HAPARIN (View Haparin Review and Haparin Label ), LAMOTRIL (View Lamotril Review and Lamotril Label ), CHLORHEXIDINE GLUCONATE (View Chlorhexidine Gluconate Review and Chlorhexidine Gluconate Label ), LASIX (View Lasix Review and Lasix Label ), GABAPENTIN (View Gabapentin Review and Gabapentin Label ), NYSTATIN (View Nystatin Review and Nystatin Label ), SEROQUEL (View Seroquel Review and Seroquel Label ), TRICLYCIN (SP) (View Triclycin (sp) Review and Triclycin (sp) Label ).

5787695-5 | Diarrhoea
Adverse event was reported on Jun 24, 2008 by a Male patient taking Repaglinide (View Usage) (Dosage: 0.5 Mg Tid Po) was diagnosed with diabetes mellitus and. Location: UNITED STATES , 56 years of age, weighting 158.0 lb, Patient experienced the following unwanted or unexpected effects: diarrhoea.

5766671-2 | Cholestasis
on May 30, 2008 Female patient from SPAIN , 72 years of age, was diagnosed with type 2 diabetes mellitus, depression (What is depression?), hypertension, cardiac disorder, osteoarthritis (What is osteoarthritis?) and was treated with Repaglinide (View Usage). Patient had the following side effects: cholestasis. Repaglinide dosage: . During the same period patient was treated with CITALOPRAM HYDROBROMIDE (View Citalopram Hydrobromide Review and Citalopram Hydrobromide Label ), ENALAPRIL MALEATO (View Enalapril Maleato Review and Enalapril Maleato Label ), ATORVASTATINA (View Atorvastatina Review and Atorvastatina Label ), CONDROITINA (View Condroitina Review and Condroitina Label ). Patient was hospitalized.

5759304-2 | Acute Hepatic Failure
on Apr 29, 2005 Male patient from SWEDEN , 61 years of age, was diagnosed with insulin-requiring type 2 diabetes mellitus and was treated with Repaglinide (View Usage). After Repaglinide was administered, patient had the following side effects: acute hepatic failure. Repaglinide dosage: .5 Unk, Bid. During the same period patient was treated with INSULATARD (4 Iu, Qd) (View Insulatard Review and Insulatard Label ). Patient was hospitalized.

5758221-1 | Dehydration, Diarrhoea, Renal Failure
Patient was taking Repaglinide (View Usage). Patient experienced the following unwanted or unexpected effects: dehydration, diarrhoea, renal failure on May 26, 2008 from ITALY Additional patient health information: Male patient , 65 years of age, was diagnosed with diabetes mellitus and. Repaglinide dosage: .75 Mg, Qd. During the same period patient was treated with EPARINA CALCICA (1 Ml, Qd) (View Eparina Calcica Review and Eparina Calcica Label ), CORDARONE (200 Mg, Qd) (View Cordarone Review and Cordarone Label ), NORVASC (10 Mg, Qd) (View Norvasc Review and Norvasc Label ). Patient was hospitalized.

5753436-0 | Blister
Adverse event was reported on May 21, 2008 by a Female patient taking Repaglinide (View Usage) (Dosage: ) . Location: BELGIUM , 68 years of age, weighting 187.4 lb, Patient had the following side effects: blister. During the same period patient was treated with LASIX (View Lasix Review and Lasix Label ), ALDACTAZINE (Altizide 15mg + Spironolactone 25mg) (View Aldactazine Review and Aldactazine Label ), PYRIDOXINE /00058902/ (View Pyridoxine /00058902/ Review and Pyridoxine /00058902/ Label ), BURINEX (View Burinex Review and Burinex Label ), SELECTOL (View Selectol Review and Selectol Label ), GLUCOPHAGE (View Glucophage Review and Glucophage Label ), SULFARLEM /00558302/ (View Sulfarlem /00558302/ Review and Sulfarlem /00558302/ Label ), DOMPERIDONE (View Domperidone Review and Domperidone Label ).

5752315-2 | Acute Hepatic Failure
on Apr 29, 2005 Male patient from SWEDEN , 61 years of age, was diagnosed with insulin-requiring type 2 diabetes mellitus and was treated with Repaglinide (View Usage). After Repaglinide was administered, patient had the following side effects: acute hepatic failure. Repaglinide dosage: .5 Unk, Bid. During the same period patient was treated with INSULATARD (4 Iu, Qd) (View Insulatard Review and Insulatard Label ). Patient was hospitalized.

5750419-1 | Aphasia, Hypoglycaemic Coma
on May 23, 2008 Female patient from FRANCE , 80 years of age, was diagnosed with diabetes mellitus and was treated with Repaglinide (View Usage). Patient experienced the following unwanted or unexpected effects: aphasia (What is aphasia?), hypoglycaemic coma. Repaglinide dosage: 2 Mg, Qd. During the same period patient was treated with NOVOLOG MIX 70/30 (20iu Am. 22iu Pm, Qd) (View Novolog Mix 70/30 Review and Novolog Mix 70/30 Label ), STAGID (View Stagid Review and Stagid Label ). Patient was hospitalized.

5730207-2 | Purpura
Patient was taking Repaglinide (View Usage). Patient had the following side effects: purpura on Apr 25, 2008 from ARGENTINA Additional patient health information: Female patient , 87 years of age, was diagnosed with type 2 diabetes mellitus and. Repaglinide dosage: . Patient was hospitalized.

5066642-8 | Blood Glucose Decreased, Diplopia, Dizziness, Hyperkalaemia, Renal Failure, Urinary Tract Infection, Vision Blurred
Adverse event was reported on Jul 19, 2006 by a Male patient taking Repaglinide (View Usage) (Dosage: ) was diagnosed with diabetes mellitus and. Location: UNITED STATES , 70 years of age, weighting 148.4 lb, After Repaglinide was administered, patient had the following side effects: blood glucose decreased, diplopia, dizziness (What is dizziness?), hyperkalaemia, renal failure, urinary tract infection (What is urinary tract infection?), vision blurred. Patient was hospitalized.